Category: Publications

13

Feb2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
February 13, 2023

16

Jan2023

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
January 16, 2023

11

Nov2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
November 11, 2022

11

Nov2022

Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)

0  
November 11, 2022

11

Nov2022

Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with nab-sirolimus, showing durability of response and long-term safety

0  
November 11, 2022

27

Oct2022

KRAS G12C-Mutated NSCLC and Bladder Cancer Xenografts Treated With Sotorasib and Adagrasib in Combination With the mTOR Inhibitor nab-Sirolimus Show Improved Antitumor Activity

0  
October 27, 2022

15

Oct2022

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

0  
October 15, 2022

15

Sep2022

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)

0  
September 15, 2022

05

Jun2022

nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program

0  
June 5, 2022

13

Nov2021

nab-Sirolimus in Patients with Malignant PEComa Previously Treated With mTOR Inhibitors: Emerging Experience From An Expanded Access Program

0  
November 13, 2021